Ascendis Pharma A (ASND) EBIAT (2016 - 2025)
Historic EBIAT for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$39.1 million.
- Ascendis Pharma A's EBIAT rose 495.43% to -$39.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$111.3 million, marking a year-over-year increase of 7286.88%. This contributed to the annual value of -$257.7 million for FY2025, which is 16378.46% down from last year.
- Ascendis Pharma A's EBIAT amounted to -$39.1 million in Q4 2025, which was up 495.43% from $71.3 million recorded in Q3 2025.
- Ascendis Pharma A's 5-year EBIAT high stood at $140.9 million for Q1 2022, and its period low was -$211.6 million during Q4 2022.
- Its 5-year average for EBIAT is -$83.6 million, with a median of -$104.2 million in 2025.
- In the last 5 years, Ascendis Pharma A's EBIAT plummeted by 25475.98% in 2021 and then skyrocketed by 16544.77% in 2025.
- Ascendis Pharma A's EBIAT (Quarter) stood at -$121.3 million in 2021, then crashed by 74.41% to -$211.6 million in 2022, then soared by 55.83% to -$93.5 million in 2023, then soared by 56.02% to -$41.1 million in 2024, then increased by 4.95% to -$39.1 million in 2025.
- Its last three reported values are -$39.1 million in Q4 2025, $71.3 million for Q3 2025, and -$44.0 million during Q2 2025.